The present invention provides methods for inhibiting or attenuating the growth of a tumor that is resistant to a blockade of EGFR, which include administering an EGFR inhibitor, an EGFR inhibitor and a FGFR inhibitor, or an EGFR inhibitor, an FGFR inhibitor and an ErbB3 inhibitor to a subject having a tumor that is or may become resistant to the blockade of EGFR. Blockade of EGFR, FGFR and/or ErbB3 may be effectuated using target specific antibodies or fragments thereof, small molecule tyrosine kinase inhibitors or a combination thereof.
